

## **Yellow Fever Training - Course Reference**

1. World Health Organization. Informal Working Group on Geographic Risk of Yellow Fever. Background for the Consultation on Yellow Fever and International Travel, 2010: February, Stockholm, 2011. Available at: <http://www.who.int/ith/YFrisk.pdf>
2. Monath T. YF: an update. *The Lancet Infectious Diseases* 1: 11-20, 2001
3. Heyman D, (ed.). *Control of Communicable Diseases Manual*. 18th edn. Washington; American Public Health Association: 2004
4. US Centers for Disease Control and Prevention. Yellow Fever. Ch 3. In: *Health Information for International Travel*. 2018. Available at: <https://wwwnc.cdc.gov/travel/yellowbook/2016/infectious-diseases-related-to-travel/yellow-fever>
5. European Centre for Disease Prevention and Control. Rapid Risk Assessment Yellow fever among travellers returning from South America. 14 March 2017. Available at: <http://ecdc.europa.eu/en/publications/Publications/14-03-2017-RRA-Yellow%20fever,%20Flaviviridae-Suriname,%20Southern%20America.pdf>
6. Newman A.P., Becraft, R. Dean A.B. et al Notes from the Field: Fatal Yellow Fever in a Traveler Returning From Peru — New York, 2016. *MMWR* September 1, 2017 / 66(34);914–915 Available at: <https://www.cdc.gov/mmwr/volumes/66/wr/mm6634a5.htm>
7. World Health Organization. Background Paper on Yellow Fever Vaccine. SAGE Working Group 19th March 2013. Available at: [http://www.who.int/immunization/sage/meetings/2013/april/1\\_Background\\_Paper\\_Yellow\\_Fever\\_Vaccines.pdf](http://www.who.int/immunization/sage/meetings/2013/april/1_Background_Paper_Yellow_Fever_Vaccines.pdf)
8. World Health Organization. Vaccines and vaccination against yellow fever. WHO Position Paper - June 2013; 88, 269-284 Available at <http://www.who.int/wer/2013/wer8827.pdf?ua=1>
9. Sanofi Pasteur. Summary of Product Characteristics – Stamaril. Updated 23 March 2017. Available at: <http://www.medicines.org.uk/emc/medicine/9846>
10. Public Health England. Chapter 4 Immunisation Procedures. Immunisation against infectious disease. Updated chapter available at: <https://www.gov.uk/government/publications/immunisation-procedures-the-green-book-chapter-4>
11. Public Health England. Chapter 35 Yellow fever. Immunisation against infectious disease. Updated chapter available at: <https://www.gov.uk/government/publications/yellow-fever-the-green-book-chapter-35>
12. Public Health England Chapter 6 Contraindications and special considerations. Immunisation against infectious disease. Updated chapter available at: <https://www.gov.uk/government/publications/contraindications-and-special-considerations-the-green-book-chapter-6>

13. Centers for Disease Control and Prevention. Transmission of yellow fever vaccine virus through breast feeding – Brazil, 2009. MMWR: 59(05); 130-132, 2010. Available at: <http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5905a2.htm>
14. World Health Organization. Global Advisory Committee on Vaccine Safety, Wkly Epidemiol Rec. 16–17 June 2010; July 23; 30(85): 285-292, 2010. Available at: <http://www.who.int/wer/2010/wer8530.pdf>
15. Kuhn S, Twele-Montecinos L, MacDonald J et al. Case report: probable transmission of vaccine strain of yellow fever virus to an infant via breast milk. CMAJ; March 8; 183(4): E243-E245, 2011. Available at: <http://www.ecmaj.ca/content/183/4/E243.full.pdf+html>
16. Suzano CES, Amaral E, Sato HK et al. The effects of yellow fever immunization (17DD) inadvertently used in early pregnancy during a mass campaign in Brazil. Vaccine; 24(9): 1421-1426, 2006.
17. British HIV Association guidelines on the use of vaccines in HIV-positive adults 2015. Available at: <http://www.bhiva.org/vaccination-guidelines.aspx>
18. Khromava AY, Eidex RB, Weld LH, et al. Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine; 23: 3256–63, 2005
19. Lindsey NP, Rabe IB, Miller ER et al. Adverse event reports following yellow fever vaccination, 2007-13. J. Trav Med. Jul 4 2016; 23 (5)
20. Barwick Eidex R, for the Yellow Fever Vaccine Safety Working Group. History of thymoma and yellow fever vaccination. Lancet; September 11; 364(9438): 936, 2004
21. MMWR. Yellow Fever: Recommendations of the Advisory Committee on Immunisation Practices (ACIP). July 30, 2010;59(RR07);1-27, 2010. Available at: <http://www.cdc.gov/mmwr/pdf/rr/rr5907.pdf>
22. Martin M, Weld LH, Tsai TF, et al. GeoSentinel Yellow Fever Working Group. Advanced age a risk factor for illness temporally associated with yellow fever vaccination. Emerg Infect Dis; 7(6): 945-51, 2001
23. Medicines and Healthcare products Regulatory Agency (MHRA). Yellow Card Scheme. Available at: <https://yellowcard.mhra.gov.uk/>
24. Sanofi Pasteur Adverse Event Reporting Contact . Available at: <http://www.sanofi.co.uk/l/gb/en/layout.jsp?cnt=73627111-97CA-4114-8356-C1BAE01C3292>
25. NaTHNaC Yellow Fever Zone Clinical Information. Management and reporting adverse. Available at: <https://nathnacyfzone.org.uk/factsheet/59/management-and-reporting-adverse-events>



26. Gershman M.D. Staples J.E. Yellow fever. In Health Information for International Travel 2016, Chapter 3, 346-360, Centers for Disease Control and Prevention (CDC), Oxford University Press. Also available at: <http://wwwnc.cdc.gov/travel/yellowbook/2016/infectious-diseases-related-to-travel/yellow-fever>